Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors
CUDC-101(一种针对 HDAC、EGFR 和 HER2 的多靶点抑制剂)针对晚期实体肿瘤患者的 I 期首次人体研究
期刊:Clinical Cancer Research
影响因子:10
doi:10.1158/1078-0432.CCR-14-0570
Toshio Shimizu, Patricia M LoRusso, Kyri P Papadopoulos, Amita Patnaik, Muralidhar Beeram, Lon S Smith, Drew W Rasco, Theresa A Mays, Glenda Chambers, Anna Ma, Jing Wang, Robert Laliberte, Maurizio Voi, Anthony W Tolcher